贝伐珠单抗治疗复发恶性脑胶质瘤36例临床分析

发布时间：2018-03-25 11:53

本文选题：神经胶质瘤　切入点：贝伐珠单抗　出处：《广东医学》2017年01期

【摘要】：目的评价贝伐珠单抗治疗复发恶性脑胶质瘤的疗效及不良反应。方法回顾性分析36例接受过贝伐珠单抗单药或联合化疗治疗的复发恶性脑胶质瘤患者的临床资料并进行生存随访,所有患者既往均接受过手术、放疗联合替莫唑胺化疗后肿瘤复发进展。按神经肿瘤疗效评价标准评价客观疗效,Kaplan-Meier法行生存分析,不良反应评价按CTC 3.0版标准。结果 36例患者的客观有效率为58.3%,中位无进展生存时间为4个月,中位总生存时间为7个月。主要不良反应有高血压、肝功能损害和骨髓抑制,无颅内出血、血栓、胃肠穿孔等严重不良反应。结论贝伐珠单抗治疗复发恶性脑胶质瘤客观有效率高,可以延长患者生存时间,毒性可耐受。
[Abstract]:Objective to evaluate the efficacy and side effects of bevacizumab in the treatment of recurrent malignant gliomas. Methods the clinical data of 36 patients with recurrent malignant gliomas treated with bevacizumab or combined chemotherapy were retrospectively analyzed. And survival follow-up, All the patients had been operated on in the past. The tumor recurrence and progression after radiotherapy combined with temozolium chemotherapy were evaluated by Kaplan-Meier method according to the criteria for evaluation of the efficacy of nerve tumors and the survival analysis was performed by Kaplan-Meier method. Results the objective effective rate of 36 patients was 58.3, the median survival time was 4 months, and the median survival time was 7 months. The main adverse reactions were hypertension, liver function damage and bone marrow suppression. Conclusion bevacizumab is effective and effective in treating recurrent malignant gliomas, it can prolong the survival time of patients, and the toxicity can be tolerated.
【作者单位】：中山大学肿瘤防治中心神经外科/神经肿瘤科华南肿瘤学国家重点实验室癌症医学协同创新中心;
【分类号】：R739.41

【相似文献】